Related Experiment Video
Updated: Feb 18, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
Studies on in-vitro hypoglycemic effects of root bark of Caesalpinia bonducella
1Department of pharmacognosy, Government college of pharmacy, Dist-Satara, 415124 Karad, Maharashtra, India.
Objective:
The present investigation was undertaken to assess the hypoglycemic potential of ethanolic (ECB) and aqueous extracts (ACB) of root bark of Caesalpinia bonducella using various in vitro techniques.
Method:
The ethanolic and aqueous extracts of root bark of C. bonducella were studied for their effects on glucose adsorption capacity, in vitro glucose diffusion, in-vitro amylolysis kinetics and glucose transport across membrane of yeast cells.
Result:
It was observed that the extracts under study adsorbed glucose and the adsorption of glucose increased remarkably with an increase in glucose concentration. The results of amylolysis kinetic experimental model revealed that the rate of glucose diffusion was found to be increased with time from 30 to 180min and both the extracts demonstrated significant inhibitory effects on movement of glucose into external solution across dialysis membrane as compared to control. Also, the extracts under study promoted glucose uptake by the yeast cells. It was observed that the enhancement of glucose uptake was dependent on both the sample and glucose concentration. Ethanolic extract of C. bonducella extract exhibited significantly higher (P≤0.05) activity than the aqueous extract at all concentrations.
Conclusion:
The results of the study verified the hypoglycemic activity of the extracts of root bark of C. bonducella. However, the observed effects need to be confirmed by using different in vivo models and clinical trials for its effective utilization as a therapeutic agent in effective management of diabetes mellitus.
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Oral Hypoglycemic Agents: Sulfonylureas
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Glinides
Oral Hypoglycemic Agents: Biguanides and Glitazones
Insulin Secretory Vesicles

